罗沙司他对脏器损伤后修复效应的研究进展

Research progress of roxadustat on repair effect of organ damage

罗沙司他是缺氧诱导因子脯氨酸羟化酶抑制剂(HIF-PHI)中最优的小分子口服药物,现已完成其用于治疗肾性贫血的Ⅲ期临床试验并批准在中国大陆首先上市。目前,罗沙司他主要用于肾性贫血的治疗,但罗沙司他还具有很多的其他药理作用。它不仅可以诱导机体产生缺氧反应,促进内源性促红细胞生成素(EPO)产生、降低铁调素、调节铁代谢等刺激骨髓造血,还可能在肾脏、神经、视网膜、皮肤、肝脏等非造血脏器损伤后具有重要的修复作用,尤其在相应器官移植、创伤愈合、缺氧耐受、抗纤维化方面的作用不可忽视。为进一步研究、开发罗沙司他的临床适应证,本文就罗沙司他相关的器官保护作用进行综述。

Roxadustat is a optimal small molecule oral drug in hypoxia-inducible factor prolyl hydroxylase inhibitors(HIF-PHI),has completed its phaseⅢclinical trials for the treatment of renal anemia and has been approved to be firstly marketed in the Chinese mainland.At present,roxadustat is mainly used in the treatment of renal anemia,but it also has many other pharmacological effects.It not only can induce the body to produce the hypoxia response,promote the endogenous erythropoietin(EPO)production,reduce hepcidin and regulate iron metabolism to stimulate bone marrow hematopoiesis,but also play an important repair role in the damage of the non-hematopoietic organs such as kidneys,nerves,retinas,skin,liver,especially its effects in the aspects of the corresponding organ transplantation,wound healing,hypoxia tolerance and anti-fibrosis are non-negligible.In order to further study and develop the clinical indications of roxadustat,this article reviews the related organ protection effects of roxadustat.